{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Time to progression was defined as the time from start date of treatment to the date of the first documentation of PD. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm and unequivocal progression of pre-existing lesions.","groups":[{"description":"Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.","id":"OG000","title":"Part 2: PF-07263689 + Sasanlimab"}],"populationDescription":"Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.","reportingStatus":"POSTED","timeFrame":"From start date of treatment to the date of first documentation of PD (up to 2 years)","title":"Part 2: Time to Progression","type":"SECONDARY"}